Advanced Search

Submit Manuscript



Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Hong Zheng1,† , Yunlong Cao2,3,†,* , Xiaosu Chen4,† , Fengmei Wang5 , Ye Hu4 , Weiliang Song3 , Yangyang Chai6 , Qingqing Gu2 , Yansong Shi4 , Yingmei Feng7 , Shuxun Liu8 , Yan Xie1 , Xiaoliang Sunney Xie2,3 , Wentao Jiang1 , Zhongyang Shen1,*

1Organ Transplant Center, NHC Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China
2Changping Laborarty, Beijing, China
3Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China
4Frontier Research Center for Cell Response, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin, China
5Institute of Hepatobiliary Disease, Tianjin Third Central Hospital, Tianjin, China
6Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China
7Beijing Youan Hospital, Capital Medical University, Beijing, China
8National Key Laboratory of Medical Immunology, Institute of Immunology, Navy Medical University, Shanghai, China
These authors contributed equally: Hong Zheng, Yunlong Cao, Xiaosu Chen
* Correspondence: Yunlong Cao( Shen(

Dear Editor,

SARS-CoV-2 Omicron variant BA.1 first emerged on the Chinese mainland on January 8, 2022, in Tianjin and caused a large wave of infections.1 Four rounds of mass testing of its ~14 million residents were launched on January 9, 12, 15, and 20, respectively. As of February 7, 2022, a total of 430 individuals were tested positive for Omicron BA.1, with no new infections detected for the following 16 days.


Browse 223